相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
50.0%
尚未招募
1
50.0%
暂无批准数据
- Telix Pharmaceuticals opens TMS North Melbourne, a first-of-its-kind Australian facility integrating radiopharmaceutical R&D, manufacturing, and patient administration under one roof. - The facility aims to address manufacturing capacity constraints and reduce the timeline from early-stage trials to broad patient access for novel radiopharmaceuticals. - Patient care and research will be delivered in collaboration with the Melbourne Theranostic Innovation Centre, led by Professor Rod Hicks. - Radiopharmaceuticals are described as the emerging 'sixth pillar' of cancer care, alongside surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
- Telix Pharmaceuticals has dosed the first patient in its Phase 1 ZOLAR trial evaluating TLX300-CDx (89Zr-olaratumab) in patients with advanced soft tissue sarcoma at Melbourne Theranostic Innovation Centre. - The first-in-human trial aims to assess safety, pharmacokinetics, and optimal dosing of the radiopharmaceutical targeting platelet-derived growth factor receptor alpha (PDGFRα), which is often overexpressed in soft tissue sarcomas. - This theranostic approach could lead to a novel targeted radionuclide therapy for soft tissue sarcoma, a rare cancer with limited treatment options and poor prognosis for patients with metastatic disease.
